Trademarkia Logo

Canada

C$
Trademark Search in Canada
REVERSE FEASIBILITY

View On IC.GC.CA

REVERSE FEASIBILITY
REGISTERED

on 10 Oct 2012

Last Applicant/ Owned by

SCIMEGA RESEARCH INC.

5764 MonklandSuite 336Montreal

QUÉBEC

CA

H4A1E9

Serial Number

1485494 filed on 17th Jun 2010

Registration Number

TMA834073 registered on 10th Oct 2012

Registration expiry Date

10th Oct 2027

Correspondent Address

BCF S.E.N.C.R.L./BCF LLP

1100, boul. René-Lévesque Ouest25e ÉtageMontréal

QUÉBEC

CA

H3B5C9

REVERSE FEASIBILITY

Trademark usage description

investigative site contract negotiations/management in the field of oncology clinical trials; data management and biostatistics, namely data processin Read More

Classification Information

Class [035]
Investigative site contract negotiations/management in the field of oncology clinical trials; data management and biostatistics, namely data processing and compilation and analysis of biostatistics in the field of oncology clinical trials; patient recruitment plans in the field of oncology clinical trials; design and production of case report forms, namely preparing forms used to enter clinical trial data, distribution and management of study materials in the field of oncology clinical trials.

Classification kind code

11

Class [036]
Investigative site budget negotiations in the field of oncology clinical trials; payments on behalf of biopharmaceutical companies in the field of oncology clinical trials.

Classification kind code

11

Class [042]
Identifying the needs and interests of investigative oncology teams concerning tumor sites, disease indications, phase and line of treatment for oncology clinical trials, to match these to the need for biopharmaceutical companies to place trials at investigative clinical research sites to fill patient recruitment needs, identifying oncology clinical trial sites with patient recruitment potential for bio-pharmaceutical companies; enhancing oncology clinical trial sites' visibility and facilitating access to oncology clinical trials for investigative oncology teams; presenting oncology clinical trial opportunities to investigative oncology teams on behalf of bio-pharmaceutical companies; providing regulatory affair services concerning pre-CTA (Clinical Trial Application) meetings with Health Canada, CTA (Clinical Trial Application) submissions, management of SAE (Serious Adverse Event) reporting to Health Canada, management of protocol amendment submissions to Health Canada, consultation on drug development plan, protocol writing, medical monitoring, namely monitoring clinical data, project management plan for the management of clinical trials, project management services for the management of clinical trials namely, using the clinical trials management plan to guide the clinical trials conduct; monitoring plan and monitoring services of clinical trials.

Classification kind code

11

Mark Details

Serial Number

1485494

Mark Type

Trademark

Legal History

Show more

Action TakenStatus
Submitted for opposition 50
on 15th Jun 2012		Allowed
Submitted for opposition 42
on 29th Feb 2012		Advertised
Submitted for opposition 26
on 9th Feb 2012		Approved
Submitted for opposition 27
on 22nd Dec 2011		Approval Notice Sent
Submitted for opposition 15
on 23rd Jun 2011		Correspondence Created
Submitted for opposition 22
on 19th Oct 2010		Search Recorded
Submitted for opposition 20
on 19th Oct 2010		Examiner's First Report
Submitted for opposition 31
on 21st Jun 2010		Formalized
Submitted for opposition 30
on 17th Jun 2010		Filed
Submitted for opposition 1
on 17th Jun 2010		Created